Willard ("Bill") E. Fee, Jr.

Clinical Focus

• Cancer > Head and Neck Cancer
• Otolaryngology
• Head and Neck Tumor Surgery
• Nasopharyngeal Cancer
• Otolaryngology/Head&Neck

Professional Education

Community & International Work

• University Grants Committee, Hong Kong 

Web Site Links

• http://med.stanford.edu/profiles/ohns/frdActionServlet?choiceId=facProfile&fid=4331

Research Interests

IRX-2 is a biologic product containing multiple ultra low dose cytokines (IL-1 beta. IL:=2,6,8,10,12, TNF- alpha, G-CSF, and GM-CSF) produced from PHA stimulated monoclear cells obtain from normal donors. Cyclophosphamide 300mg/m2 is given IV on day 1, indomethacin 25 mg p.o. tid together with oral zinc and multivitamins are given daily for 3 weeks. 1cc of IRX-2 is given into each upper sternocleidomasatoid muscle for 10 days between days 4 and 15 (not on Saturday and Sunday). Mutivitamin Supplement and Zinc will also be given. Safety and freedom from relapse will be measured for 5 years.

Clinical Trials

• Biopsy of human tumors for cancer stem cell characterization: a feasibility study Recruiting
• Identification and Characterization of Novel Proteins in Head and Neck Cancer Recruiting
• A Phase 2 Clinical Trial of the Effectiveness of IRX-2 in Treating Patients With Operable Head and Neck Cancer No longer recruiting
• Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation No longer recruiting

Publications

• Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. Hara W, Loo BW, Goffinet DR, Chang SD, Adler JR, Pinto HA, Fee WE, Kaplan MJ, Fischbein NJ, Le QT. Int J Radiat Oncol Biol Phys. 2008; 71 (2): 393-400
• Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma. Daly ME, Lieskovsky Y, Pawlicki T, Yau J, Pinto H, Kaplan M, Fee WE, Koong A, Goffinet DR, Xing L, Le QT. Head Neck. 2007; 29 (3): 211-20
• Quality of life 17 to 20 years after uvulopalatopharyngoplasty. Goh YH, Mark I, Fee WE. Laryngoscope. 2007; 117 (3): 503-6
• Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas. Le QT, Taira A, Budenz S, Jo Dorie M, Goffinet DR, Fee WE, Goode R, Bloch D, Koong A, Martin Brown J, Pinto HA. Cancer. 2006; 106 (9): 1940-9
• Advanced-staged tonsillar squamous carcinoma: organ preservation versus surgical management of the primary site. Shirazi HA, Sivanandan R, Goode R, Fee WE, Kaplan MJ, Pinto HA, Goffinet DR, Le QT. Head Neck. 2006; 28 (7): 587-94